Quarterly ResultMay 12, 2026, 04:07 PM
Sanara MedTech Q1 Net Revenue +18.6% to $27.8M; Swings to Profit
AI Summary
Sanara MedTech Inc. reported a significant financial turnaround for the first quarter ended March 31, 2026, with net revenue increasing by 18.6% to $27.8 million and the company swinging to a net profit of $0.46 million, or $0.05 per basic share, compared to a net loss in the prior year. This improvement follows the discontinuation of the Tissue Health Plus (THP) segment in Q3 2025, which was substantially complete by year-end 2025. The company also reduced earnout liabilities to zero due to non-renewal of the Petito Services Agreement and the discontinuation of THP.
Key Highlights
- Net Revenue increased by 18.6% to $27,798,534 for Q1 2026, up from $23,434,096 in Q1 2025.
- Net income attributable to shareholders was $458,957 ($0.05 basic EPS) for Q1 2026, a significant improvement from a net loss of $(3,527,177) ($(0.41) basic EPS) in Q1 2025.
- Operating income surged to $2,646,581 in Q1 2026, compared to $825,530 in Q1 2025.
- Soft tissue repair product revenue grew to $24,942,945 in Q1 2026 from $20,532,440 in Q1 2025.
- Net income from discontinued operations improved to $60,916 in Q1 2026 from a loss of $(2,906,817) in Q1 2025.
- Earnout liabilities were reduced to zero as of March 31, 2026, following the discontinuation of the THP segment and non-renewal of the Petito Services Agreement.
- Cash balance was $13,594,459 as of March 31, 2026, down from $16,578,857 at December 31, 2025.
Price Impact
More from SMTI